Infección de vías urinarias no complicada en mujeres

Resumen

La infección de vías urinarias (IVU) es una patología común, que afecta a gran parte de la población y que generalmente se resuelve con manejo antibiótico. Se compone de una amplia variedad de entidades clínicas que pueden variar desde una cistitis no complicada hasta un shock séptico de origen urinario. Los patógenos etiológicos de la IVU no complicada están ampliamente establecidos y se han mantenido de forma consistente a lo largo del tiempo, siendo la Escherichia coli el microorganismo más predominante. En la actualidad, la resistencia bacteriana a los antibióticos es de gran preocupación y por esa razón, se busca optimizar la terapia antimicrobiana con el fin de disminuir la estancia hospitalaria, la severidad clínica de la infección y los costos a los sistemas de salud. La presente revisión, tiene como objetivo servir como guía para la correcta definición, clasificación, diagnóstico, tratamiento y prevención de la IVU no complicada.

Abstract

A urinary tract infection (UTI) is a common pathology, that affects a large part of the population and generally resolves with antibiotic treatment. It embraces a variety of clinical entities that can vary from uncomplicated cystitis to septic shock. The etiological pathogens of uncomplicated UTI are widely established and have been consistent over time, with Escherichia coli being the most predominant microorganism. Currently, bacterial resistance to antibiotics is of great concern and for this reason we seek to optimize antimicrobial therapy in order to decrease hospital stay, clinical severity of the infection and costs to the health systems. The purpose of this review is to serve as a guide for the correct definition, classification, diagnosis, treatment and prevention of uncomplicated UTI.

Palabras clave

infección - tracto urinario - cistitis no complicada - resistencia - prevención - terapia antibiótica

Keywords

infection - urinary tract - uncomplicated cystitis - resistance - prevention - antibiotic treatment

Publication History

Received: 20 July 2020

Accepted: 01 September 2020

Article published online:
04 February 2021

• Referencias

• 1 Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Curr Opin Infect Dis 2016; 29 (01) 73-79 DOI: 10.1097/QCO.0000000000000228.
• 2 Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012; 366 (11) 1028-1037 DOI: 10.1056/NEJMcp1104429.
• 3 Prada G, Plata M. GUIA DE PRACTICA CLINICA DE INFECCION URINARIA. 2016
• 4 Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003; 17 (02) 227-241 DOI: 10.1016/S0891-5520(03)00005-9.
• 5 Kaye KS, Pogue JM. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Pharmacotherapy 2015; 35 (10) 949-962 DOI: 10.1002/phar.1636.
• 6 Gupta K, Trautner BW. Urinary Tract Infection, Pyelonephritis, and Prostatitis. In: Harrison's Principles of Internal Medicine. 20th ed.. New York: McGrar-Hill Education; 2018. http://accessmedicine.mhmedical.com/content.aspx?aid=1159153646
• 7 Bonkat G, Bartoletti R, Bruyère F. et al. EAU Guidelines on Urological Infections. In: EAU Guidelines. presented. Arnhem: EAU Guidelines Office; 2020. https://uroweb.org/guideline/urological-infections/
• 8 File TM. Highlights from international clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the infectious diseases society of America and the european society for microbiology and infectious. Infect Dis Clin Pract 2011; 19 (04) 282-283 DOI: 10.1097/IPC.0b013e3182231994.
• 9 Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J 2011; 5 (05) 316-322 DOI: 10.5489/cuaj.11214.
• 10 Hooton TM. Recurrent urinary tract infections in non-pregnant adult women. S Afr Fam Pract 2009; 51 (06) 467-470 DOI: 10.1080/20786204.2009.10873905.
• 11 Cai T, Koves B, Bjerklund TE. Asymptomatic bacteriuria, to screen or not to screen – and when to treat ?. 2017; 107-111 DOI: 10.1097/MOU.0000000000000368.
• 12 Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA 2014; 312 (16) 1677-1684 DOI: 10.1001/jama.2014.12842.
• 13 Rhodes A, Evans LE, Alhazzani W. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. Vol 45. Springer Berlin Heidelberg 2016; 2017 DOI: 10.1097/CCM.0000000000002255.
• 14 Wagenlehner FME, Pilatz A, Weidner W, Naber KG. Urosepsis: Overview of the Diagnostic and Treatment Challenges. Microbiol Spectr 2015; 3 (05) 1-18 DOI: 10.1128/microbiolspec.uti-0003-2012.
• 15 Wagenlehner FME, Tandogdu Z. An update on classification and management of urosepsis. 2017; 133-137 DOI: 10.1097/MOU.0000000000000364.
• 16 Geerlings SE, Bartoletti R, Pilatz A. et al. Management of Urosepsis in 2018; 2018 (05) 5-9 DOI: 10.1016/j.euf.2018.11.003.
• 17 Anger J, Lee U, Ackerman AL. et al. Infection / Inflammation Recurrent Uncomplicated Urinary Tract Infections in Women. 2019; 202 (August): 282-289
• 18 Orrego-Marín CP, Henao-Mejía CP, Cardona-Arias JA. Prevalencia de infección urinaria, uropatógenos y perfil de susceptibilidad antimicrobiana. Acta Med Colomb 2014; 39: 352-358 http://www.scielo.org.co/pdf/amc/v39n4/v39n4a08.pdf
• 19 Alviz-Amador A, Gamero-Tafur K, Caraballo-Marimon R, Gamero-Tafur J. Prevalencia de infección del tracto urinario, uropatógenos y perfil de susceptibilidad en un hospital de Cartagena, Colombia. 2016. Rev Fac Med (Caracas) 2018; 66 (03) 313-317 DOI: 10.15446/revfacmed.v66n3.62601.
• 20 Foxman B, Geiger AM, Palin K, Gillespie B, Koopman JS. First-time urinary tract infection and sexual behavior. Epidemiology 1995; 6 (02) 162-168 DOI: 10.1097/00001648-199503000-00013.
• 21 Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000; 182 (04) 1177-1182 DOI: 10.1086/315827.
• 22 Raz R, Gennesin Y, Wasser J. et al. Recurrent Urinary Tract Infections in Postmenopausal Women. Clin Infect Dis 2000; 30 :152.156 DOI: 10.1086/313596.
• 23 Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4 (12) e329 DOI: 10.1371/journal.pmed.0040329.
• 24 Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 13 (05) 269-284
• 25 Hung C, Bouckaert J, Hung D. et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. 2002; 44: 903-915
• 26 Duell BL, Carey AJ, Tan CK. et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 2012; 188 (02) 781-792 DOI: 10.4049/jimmunol.1101231.
• 27 Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. 2006 103(38):
• 28 Hannan TJ, Roberts PL, Riehl TE. et al. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine 2014; 1 (01) 46-57 DOI: 10.1016/j.ebiom.2014.10.011.
• 29 Pak J, Pu Y, Zhang ZT, Hasty DL, Wu XR. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 2001; 276 (13) 9924-9930 DOI: 10.1074/jbc.M008610200.
• 30 Waksman G, Hultgren SJ. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat Rev Microbiol 2009; 7 (11) 765-774 DOI: 10.1038/nrmicro2220.
• 31 Vauré C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol 2014; 5 (316) 316 DOI: 10.3389/fimmu.2014.00316.
• 32 Robinson AE, Lowe JE, Koh E, Henderson JP. Uropathogenic enterobacteria use the yersiniabactin metallophore system to acquire nickel. 2018; 293 (19) ):14953-14961 DOI: 10.1074/jbc.RA118.004483.
• 33 Su Q, Guan T, He Y, Lv H. Siderophore biosynthesis governs the virulence of uropathogenic Escherichia coli by coordinately modulating the differential metabolism. J Proteome Res 2016; 15 (04) 1323-1332 DOI: 10.1021/acs.jproteome.6b00061.
• 34 Garcia TA, Ventura CL, Smith MA, Merrell DS, O'Brien AD. Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder. Infect Immun 2013; 81 (01) 99-109 DOI: 10.1128/IAI.00605-12.
• 35 Goller CC, Seed PC. Revisiting the Escherichia coli polysaccharide capsule as a virulence factor during urinary tract infection: contribution to intracellular biofilm development. Virulence 2010; 1 (04) 333-337 DOI: 10.1126/science.1084550.
• 36 Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med 2006; 119 (06, Suppl 1): discussion S62–S70 S20-S28 DOI: 10.1016/j.amjmed.2006.03.013.
• 37 Gupta K, Bhadelia N. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am 2014; 28 (01) 49-59 DOI: 10.1016/j.idc.2013.10.002.
• 38 Huang B, Fettweis JM, Brooks JP, Jefferson KK, Buck GA. The changing landscape of the vaginal microbiome. Clin Lab Med 2014; 34 (04) 747-761 DOI: 10.1016/j.cll.2014.08.006.
• 39 Swidsinski A, Loening-Baucke V, Mendling W, Swidsinski S. Positive effects of local therapy with a vaginal lactic acid gel on dysuria and E.coli bacteriuria question our current views on recurrent cystitis. Arch Gynecol Obstet 2012; 285 (06) 1619-1625 DOI: 10.1007/s00404-011-2196-z.
• 40 Zárate G, Nader-Macias ME. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. Lett Appl Microbiol 2006; 43 (02) 174-180 DOI: 10.1111/j.1472-765X.2006.01934.x.
• 41 O'Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One 2013; 8 (11) e80074 DOI: 10.1371/journal.pone.0080074.
• 42 Grabe M, Bjeklund T, Botto H, Naber G, Tenke P, Wangenlehner F. Guia clínica sobre las infecciones urológicas. Eur Assoc Urol 2010; 1-136 http://www.aeu.es/UserFiles/17-GUIA_CLINICA_SOBRE_LAS_INFECCIONES_UROLOGICAS.pdf
• 43 Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003; 49 (02) 71-82 DOI: 10.1016/S0011-5029(03)90001-0.
• 44 Caicedo PS, Martinez T, Meneses E. et al. Etiologia y resistencia bacteriana en infección de vías urinarias en el hospital universitario san jose de popayan, colombia entre enero y diciembre de 2008. Urol Colomb 2009; 13 (03) 45-52 http://www.urologiacolombiana.com/userfiles/file/6-ETILOGIAYRESISTENCIABACTERIANA.pdf
• 45 Machado-Alba JE, Murillo-Muñoz MM. Evaluación de sensibilidad antibiótica en urocultivos de pacientes en primer nivel de atención en salud de Pereira. Rev Salud Publica (Bogota) 2012; 14 (04) 710-719 http://www.scielo.org.co/scielo.php?pid=S0124-00642012000400014&script=sci_abstract&tlng=es
• 46 Gómez C, Plata M, Sejnaui J, Rico C, González S. Resistencia de la E.coli en urocultivos de pacientes con sospecha de infección urinaria intr y extra-hospitalaria en la Fundación Santa Fe de Bogotá. Urol Colomb 2009; 18 (01) 8
• 47 Campuzano G, Arbeláez M. El Uroanálisis: Un gran aliado del médico. Rev Urol Colomb 2007; XVI (01) 67-92
• 48 Moyes RB, Reynolds J, Breakwell DP. Differential staining of bacteria: gram stain. Curr Protoc Microbiol 2009; 3 (Appendix, SUPPL. 15) 3C DOI: 10.1002/9780471729259.mca03cs15.
• 49 Wein AJ, Kolon TF, Partin AW. Campbell-Walsh-Wein Urology Twelfth Edition. 1141
• 50 Microbitos G. Pruebas bioquímicas primarias: Tinción de GRAM, prueba de catalasa, prueba de oxidasa, prueba de O/F y motilidad. http://microbitosblog.com/2011/09/27/pruebas-bioquimicas-primarias/ . Published 2015
• 51 Tille PM. Bailey & Scott's Diagnostic Microbiology. 14th ed.. Elsevier; 2017
• 52 Cortes JA, Perdomo D, Morales R. et al. Guía de práctica clínica sobre diagnóstico y tratamiento de infección de vías urinarias no complicada en mujeres adquirida en la comunidad. 2015; 63 (04) 565-581
• 53 Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect 2009; 58 (02) 91-102 DOI: 10.1016/j.jinf.2008.12.009.
• 54 Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7 (12) 653-660 DOI: 10.1038/nrurol.2010.190.
• 55 Gilbert DN, Chambers HF, Saag MS. et al. The Sanford Guide To Antimicrobial Therapy 2020. 50th ed.. Sperryville: Antimicrobial Therapy, INC; 2020
• 56 Bassetti M, Giacobbe DR, Giamarellou H. et al; Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Disease (ESCMID); Hellenic Society of Chemotherapy (HSC) and Società Italiana di Terapia Antinfettiva (SITA). Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect 2018; 24 (02) 133-144 DOI: 10.1016/j.cmi.2017.08.030.
• 57 Gupta K, Hooton TM, Naber KG. et al; Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52 (05) e103-e120 DOI: 10.1093/cid/ciq257.
• 58 Anger J, Lee U, Ackerman AL, Chughtai B, Clemens JQ, Hickling D. American Urological Association (AUA) / Canadian Urological Association (CUA) / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Recurrent Uncomplicated Urinary Tract Infections in Women: AUA / CUA / SUFU Guideline R. 2019 ;(April):1-36
• 59 Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric 2019; 22 (03) 242-249 DOI: 10.1080/13697137.2018.1551871.
• 60 Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003; 17 (02) 243-259 DOI: 10.1016/S0891-5520(03)00006-0.
• 61 Zhanel GG, Hisanaga TL, Laing NM. et al; NAUTICA Group. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27 (06) 468-475 DOI: 10.1016/j.ijantimicag.2006.02.009.
• 62 Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54 (05) 1164-1175 DOI: 10.1016/j.eururo.2008.05.010.
• 63 Beerepoot M, Geerlings SE. Non-Antibiotic Prophylaxis for Urinary Tract Infections. 2016 DOI: 10.3390/pathogens5020036
• 64 Nappi RE, Martini E, Cucinella L. et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne) 2019; 10 (August): 561 DOI: 10.3389/fendo.2019.00561.
• 65 Portman DJ, Gass MLS, Kingsberg S. et al; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21 (10) 1063-1068 DOI: 10.1097/gme.0000000000000329.
• 66 Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention. Clinics (São Paulo) 2012; 67 (06) 661-668 DOI: 10.6061/clinics/2012(06)18.
• 67 Ashraf MS, Gaur S, Bushen OY. et al; Infection Advisory SubCommittee for AMDA—The Society of Post-Acute and Long-Term Care Medicine. Diagnosis, Treatment, and Prevention of Urinary Tract Infections in Post-Acute and Long-Term Care Settings: A Consensus Statement From AMDA's Infection Advisory Subcommittee. J Am Med Dir Assoc 2020; 21 (01) 12-24.e2 DOI: 10.1016/j.jamda.2019.11.004.
• 68 Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol 2018; 15 (12) 750-776 DOI: 10.1038/s41585-018-0106-x.
• 69 Valdevenito JP. Infección urinaria recurrente en la mujer. Infectología al día 2008; 25 (04) 268-276
• 70 Sotomayor De Zavaleta M, Ponce De León Garduño A, Guzmán Esquivel J. et al. Recomendaciones de expertos mexicanos en el tratamiento de las infecciones del tracto urinario en pacientes adultos, embarazadas y niños. 2015; 75 (02) 1-46
• 71 Mensa J, Gatell J, García-Sánchez J, Letang E, López-Suñé E, Marco F. Guía de Terapéutica Antimicrobiana 2018. Antares E. ed. Barcelona: 2018
• 72 MacDougall C. Section VII: Chemotherapy of Infectious Diseases. In: Brunton LL, Hilal-Dandan R, Knollman BC. eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed.. New York: McGraw-Hill Education; 2020